Please assess the completion status of the following clinical trial:

Trial Title: GRam Stain-guided Antibiotics ChoicE for Ventilator-Associated Pneumonia (GRACE-VAP) Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing mechanical ventilation in the ICU~* Patients undergoing mechanical ventilation for at least 48 hours~* Patients diagnosed as having VAP, which is defined by a modified clinical pulmonary infection score of 5 or more~Exclusion Criteria:~* Patients having an allergy to study medications~* Pregnant patients~* Patients discharged from ICU~* Patients diagnosed as having heart failure or atelectasis~* Patients administered antibiotics for more than 24 hours when they meet the inclusion criteria~* Patients declined to provide full life support~* Patients judged as inappropriate at the discretion of the study physician.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Gram stain-guided therapy group (Type: ACTIVE_COMPARATOR): The results of Gram staining of endotracheal aspirate are used to guide the selection of antibiotics. The results of the Gram stains are categorised as Gram-positive cocci (GPC) chains, GPC clusters, Gram-positive bacilli (GPB), Gram-negative rods (GNR), or a combination of these. A non-pseudomonal beta-lactam antibiotic is selected when the Gram stain of the endotracheal aspirate shows only GPC chains and/or GPB. An anti-MRSA agent is selected when the Gram stain results show GPC clusters without GNR. An anti-pseudomonal agent is selected when the Gram stain results show GNR without GPC clusters. The combination of an anti-pseudomonal agent and an anti-MRSA agent is selected when the Gram stain results show both GPC clusters and GNR.
- Guidelines-based therapy group (Type: ACTIVE_COMPARATOR): Patients are administered the combination of an anti-pseudomonal agent and anti-MRSA agent according to the Infectious Disease Society of America and the American Thoracic Society (IDSA/ATS) guidelines because 47.7% of S. aureus isolates are MRSA in Japanese ICUs

Based on this trial design, predict the completion outcome and termination type (if applicable).